Article Information
History
- May 17, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Doreen Lau1,2,*,†,
- Mary A. McLean1,2,3,
- Andrew N. Priest1,4,
- Andrew B. Gill1,2,
- Francis Scott1,
- Ilse Patterson4,
- Bruno Carmo4,
- Frank Riemer1,
- Joshua D. Kaggie1,
- Amy Frary1,
- Doreen Milne5,
- Catherine Booth5,
- Arthur Lewis6,
- Michal Sulikowski6,
- Lee Brown6,
- Jean-Martin Lapointe6,
- Luigi Aloj1,7,
- Martin J. Graves1,4,
- Kevin M. Brindle3,
- Pippa G. Corrie6,* and
- Ferdia A. Gallagher1,2,*
- 1Department of Radiology, University of Cambridge, Cambridge, United Kingdom
- 2Cancer Research UK Cambridge Centre, Cambridge, United Kingdom
- 3CRUK Cambridge Institute, Cambridge, United Kingdom
- 4Department of Radiology, Addenbrooke’s Hospital, Cambridge, United Kingdom
- 5Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge, United Kingdom
- 6Clinical Pharmacology & Safety Sciences, AstraZeneca, United Kingdom
- 7Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom
- ↵* Correspondence to Dr. Doreen Lau (la399{at}cam.ac.uk), Dr. Pippa Corrie (pippa.corrie{at}addenbrookes.nhs.uk), Prof. Ferdia Gallagher (fag1000{at}cam.ac.uk)
Posted May 17, 2021.
Multiparametric MRI of Early Tumor Response to Immune Checkpoint Blockade in Metastatic Melanoma
